dc.contributor.author | O'Dwyer, M. E. | |
dc.date.accessioned | 2018-08-24T08:25:54Z | |
dc.date.available | 2018-08-24T08:25:54Z | |
dc.date.issued | 2004-01-15 | |
dc.identifier.citation | O'Dwyer, M. E. (2004). Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase cml patients treated with imatinib mesylate. Blood 103 (2), 451-455 | |
dc.identifier.issn | 0006-4971,1528-0020 | |
dc.identifier.uri | http://hdl.handle.net/10379/9644 | |
dc.description.abstract | We followed 141 patients treated with imatinib mesylate (>300 mg) for chronic-phase chronic myelogenous leukemia (CML) following failure of treatment with interferon. During 12 months from the start of imatinib mesylate treatment, 96.5% achieved a complete hematologic response, 47.0% achieved a major cytogenetic response, and 32.4% achieved a complete cytogenetic response. The proportion of patients with hematologic relapse was 10.9% at 12 months and 14.6% at 18 months. In a univariate Cox regression analysis, the only pretreatment characteristics that correlated with an increased risk of hematologic relapse were hemoglobin level less than 120 g/L (12 g/dL) (P=.02), increased bands in the peripheral blood (P=.01), and clonal evolution (P<.0001). In a multivariate analysis, an elevated platelet count (P=.03) and clonal evolution (P<.0001) were the only significant factors for hematologic relapse. During treatment, the absence of a major cytogenetic response within the first 6 months also significantly correlated with relapse (P=.03). Notably, patients failing to achieve a major cytogenetic response by 6 months had a significantly higher rate of hematologic relapse (27%) compared with those who achieved a major cytogenetic response by 6 months (3%), and patients with clonal evolution had a significantly higher risk of hematologic relapse (50%) than those without clonal evolution (9%). | |
dc.publisher | American Society of Hematology | |
dc.relation.ispartof | Blood | |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Ireland | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/ie/ | |
dc.subject | chronic myelogenous leukemia | |
dc.subject | chronic myeloid-leukemia | |
dc.subject | tyrosine kinase | |
dc.subject | chromosome | |
dc.subject | therapy | |
dc.title | Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase cml patients treated with imatinib mesylate | |
dc.type | Article | |
dc.identifier.doi | 10.1182/blood-2003-02-0371 | |
dc.local.publishedsource | http://www.bloodjournal.org/content/bloodjournal/103/2/451.full.pdf | |
nui.item.downloads | 0 | |